Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, participants will be able to: Explain the key characteristics of an oncolytic immunotherapy for advanced melanoma; Discuss the rationale for combining an oncolytic immunotherapy and a systemic immunotherapy in patients with melanoma who have progressed on an anti-PD1 therapeutic regimen; Evaluate the latest clinical data for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma who have progressed on an anti-PD1 therapy; and Use patients and disease characteristics to identify patient eligibility and suitability for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma.

Om Podcasten

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.